Amgen announced that the FDA accepted the company’s filing for denosumab for the treatment and prevention of postmenopausal osteoporosis, and for the treatment and prevention of bone loss in patients with either prostate or breast cancer who are undergoing hormone therapy.

[ad]

Amgen said it has also made submissions to market the RANK Ligand inhibitor in the EU, Switzerland, Canada and Australia.

Source: FirstWord

Popularity: 3% [?]